An Economic Evaluation of Pharmacological Therapy and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia / 대한비뇨기과학회지
Korean Journal of Urology
;
: 619-623, 2002.
Artigo
em Coreano
| WPRIM
| ID: wpr-48129
ABSTRACT
PURPOSE:
An economic analysis of pharmacological therapy and transurethral resection of the prostate (TURP) for patients with benign prostatic hyperplasia (BPH) was conducted. MATERIALS ANDMETHODS:
Twenty six patients had undergone TURP from January to June 2000 were enrolled in this study. The costs associated with this group of patients were compared with those of 7 patients treated with medication (doxazosin, terazosin, tamsulosin, and finasteride only and alpha-blocker with finasteride).RESULTS:
The mean cost for TURP was 1,900,000 won. The most expensive medical therapy was finasteride, which was followed by tamsulosin, terazosin, and doxazosin, with an estimated 12-month cost of 817,000won, 695,000won, 396,000won, and 372,000won respectively. The costs associated with doxazosin remained lower than those associated with TURP for approximately 5.3 years (the corresponding break-even point was 2.4 years for finasteride vs. TURP).CONCLUSIONS:
Among the pharmacological therapies, doxazosin is the most cost effective. TURP was more cost effective than doxazosin therapy after 5.3 years. In view of the cost-effectiveness, TURP may be considered as the mode of primary therapy for the patients with severe symptoms of BPH.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Próstata
/
Hiperplasia Prostática
/
Doxazossina
/
Finasterida
/
Ressecção Transuretral da Próstata
Tipo de estudo:
Avaliação Econômica em Saúde
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Urology
Ano de publicação:
2002
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS